Home | Intro | Contact | Download | Literature | Links | Imprint
Literatur Zum ATP-TCA liegen zahlreiche wissenschaftliche Studienergebnisse vor. Vor allem die klinischen Studien belegen die hohe prädiktive Aussagefähigkeit des Verfahrens, das sich nicht nur bei der individuellen Therapieplanung, sondern auch in der Entwicklung innovativer Therapieregime bereits hervorragend bewährt hat.
International Literature
A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Feasibility of chemosensitivity testing in soft tissue sarcomas.
Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci.
In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer.
ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.
Chemosensitivity testing in malignant melanoma.
Chemosensitivity testing in gynecologic oncology–dream or reality?
Literature Numerous scientific studies have been published on ATP-TCA.
Particularly, the clinical studies illustrate the highly predictive value of this methodology. The ATP-TCA has not only proven to be of advantage for the individual therapy planning, but also for the development of innovative therapy regimens.

Comparison of a therapy using ATP-TCA (solid line)
with the traditional therapy (dotted line).
source: see Kurbacher CM, Cree IA, Bruckner HW, et al. *)



Andreotti PE, Cree IA, Kurbacher CM, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma, Cancer Res (1995) 55: 5276-5282.

Cree IA, Kurbacher CM, Untch M, et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anti-Cancer Drugs (1996) 7:630-635.

Kurbacher CM, Bruckner HW, Cree IA, et al. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Clin Cancer Res (1997) 3:1527-1533.

Kurbacher CM, Cree IA, Bruckner HW, et al. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anti-Cancer Drugs (1998) 9:51-57. *

Konecny G, Crohns C, Pegram M, et al. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol (2000) 77:258-263.

Sharma S, Neale MH, DiNicolantonio F, et al. Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pretreated recurrent ovarian carcinoma. BMC Cancer (2003) 3:19.

Reinhold U, Hauschild A. Diagnostische Wertigkeit von Tumormarkeruntersuchungen und Verfahren zur prätherapeutischen Chemosensitivitätstestung, Der Onkologe (2001) 7:53-60.

Reinhold U, Tilgen W (Eds.) Chemosensitivity Testing in Oncology. Recent Results in Cancer Research 161 Springer Verlag Berlin, Heidelberg, New York, 2003.


© 2004 | L.a.n.c.e. | Laboratory for Applied Neoplasia Research and Cytostatics Evaluation Inc. | powered by webunit.com